Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul;9(14):1148. doi: 10.21037/atm-21-2589

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

2021 Annals of Translational Medicine. All rights reserved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0.

PMC Copyright notice

The percentage of CD73 expression on peripheral blood MDSCs. Both M-MDSCs (A) and PMN-MDSCs (B) from HNSCC patients expressed significant high level of CD73 than those from healthy donors with mean 8.19% vs. 2.16% (P<0.0001) and 10.76% vs. 1.19% (P<0.0001). (C) No correlation was observed between CD73⁺ M-MDSCs and the clinical stage. (D) The CD73⁺ PMN-MDSCs was specifically correlated with the clinical stage (mean 7.74%, 10.32% and 14.38% for stage I, II and III; stage I vs. III P<0.0001, stage II vs. III, P=0.029 respectively). * indicates a P value of <0.05; *** indicates a P value of <0.0001. MDSCs, myeloid-derived suppressor cells; PMN-MDSCs, polymorphonuclear myeloid-derived suppressor cells; HNSCC, head and neck squamous cell carcinoma; Health, healthy volunteers; Patients, HNSCC patients.